Item 1.01. Entry into a Material Definitive Agreement.
On April 7, 2022, Lyra Therapeutics, Inc. (the “Company”) entered into a Securities Purchase Agreement (the “Purchase Agreement”) with the purchasers named therein (the “Investors”), pursuant to which the Company agreed to sell securities to the Investors in a private placement (the “Private Placement”).
In the Private Placement, the Investors had the option to purchase either (a) shares of the Company’s common stock, par value $0.001 per share (the “Common Stock”), at a price of $4.22 per share, or (b) in lieu thereof, pre-funded warrants to purchase shares of Common Stock, with an exercise price of $0.001 per share, at a purchase price of $4.219 per share (for aggregate consideration equating to $4.22 per share). Accordingly, pursuant to the Purchase Agreement, the Company agreed to sell (i) an aggregate of 18,815,159 shares (the “Shares”) of Common Stock to the Investors at the purchase price described in the preceding sentence and (ii) warrants (the “Warrants”) to purchase an aggregate of 5,000,000 shares of Common Stock (the “Warrant Shares”) to certain of the Investors with the exercise price and at the purchase price described in the preceding sentence, for aggregate gross proceeds of approximately $100.5 million, before deducting private placement expenses. The closing of the Private Placement occurred on April 12, 2022 (the “Closing Date”).
On April 7, 2022, in connection with the Purchase Agreement, the Company entered into a Ninth Amended and Restated Investor Rights Agreement (the “Ninth A&R Investor Rights Agreement”) with certain Investor funds affiliated with Perceptive Advisors and North Bridge Venture Partners (the “IRA Covered Investors”). Each of the IRA Covered Investors was a party to the Company’s existing Eighth Amended and Restated Investor Rights Agreement, dated as of January 10, 2020, as amended, pursuant to which certain outstanding shares of Common Stock held by such IRA Covered Investors constituted “Registrable Shares” (as defined therein) and thereby were entitled to certain registration rights as more specifically set forth therein. Under the Ninth A&R Investor Rights Agreement, the Company agreed to (i) expand the definition of “Registrable Shares” to include all shares of Common Stock acquired by the IRA Covered Investors in the Private Placement, all shares of Common Stock acquired by the IRA Covered Investors prior to April 7, 2022 and any shares of Common Stock issued in respect of such shares because of stock dividends, splits or combinations of securities, reclassifications, recapitalizations or similar events and (ii) make certain other modifications to the terms of the registration rights therein for the benefit of the IRA Covered Investors.
In addition, pursuant to the Ninth A&R Investor Rights Agreement, the Company also agreed that:
| | • | | for so long as the IRA Covered Investor fund affiliated with Perceptive Advisors (and/or its affiliates) beneficially owns: |
| | • | | 20% or greater of the Company’s total voting securities outstanding, the Company shall take all reasonable actions within its control to include in the slate of nominees recommended by the Board of Directors and/or the applicable committee thereof for election as directors at each applicable annual or special meeting of stockholders at which directors are to be elected (the “Slate”), a number of individuals designated by such Perceptive Advisors fund (each, a “Perceptive Designee”) that, if elected, would result in at least two Perceptive Designees serving on the Board of Directors; and |
| | • | | 10% or greater but less than 20% of the Company’s total voting securities outstanding, the Company shall take all reasonable actions within its control to include in the Slate a number of Perceptive Designees that, if elected, would result in at least one Perceptive Designee serving on the Board of Directors; and |
| | • | | for so long as the IRA Covered Investor funds affiliated with North Bridge Venture Partners (and/or its affiliates) beneficially owns 10% or greater of the Company’s total voting securities outstanding, the Company shall take all reasonable actions within its control to include in the Slate a number of individuals designated by such North Bridge Venture Partners funds (each, a “North Bridge Designee”) that, if elected, would result in at least one North Bridge Designee serving on the Board of Directors. |
In addition, on April 7, 2022, in connection with the Purchase Agreement, the Company entered into a Registration Rights Agreement (the “Registration Rights Agreement”) with all of the Investors other than the IRA Covered
